Význam 177Lu-PSMA v léčbě kastračně-rezistentního karcinomu prostaty

Stiahnuť PDF English version

Autori: Y. Benderli Cihan
Pôsobisko autorov: Department of Radiation Oncology, Kayseri City Hospital, Kayseri, Turkey
Vyšlo v časopise: Klin Onkol 2021; 34(2): 151-152
Kategória:
doi: https://doi.org/10.48095/ccko2021151

Zdroje

1. Kulkarni HR, Singh A, Schuchardt C et al. PSMA-Based radioligand therapy for metastatic castration-resistant prostate cancer: the bad berka experience since 2013. J Nucl Med 2016; 57 (Suppl 3): 97S–104S. doi: 10.2967/jnumed.115.170167.

2. Rahbar K, Boegemann M, Yordanova A et al. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging 2018; 45 (1): 12–19. doi: 10.1007/s00259-017-3848-4.

3. Ahmadzadehfar H, Essler M. Predictive factors of response and overall survival in patients with castration-resistant metastatic prostate cancer undergoing 177Lu-PSMA therapy. J Nucl Med 2018; 59 (7): 1033–1034. doi: 10.2967/jnumed.118.209270.

4. Rahbar K, Bogeman M, Yordanova A et al. Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging 2018; 45 (2): 243–246. doi: 10.1007/s00259-017-3877-z.

5. von Eyben FE, Roviello G, Kiljunen T et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging 2018; 45 (3): 496–508. doi: 10.1007/s00259-017-3895-x.

6. von Eyben FE, Kiljunen T, Joensuu T et al. 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer. Oncotarget 2017; 8 (39): 66112–66116. doi: 10.18632/oncotarget.19805.

7. Yadav MP, Ballal S, Sahoo RK et al. Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Am J Roentgenol 2019 Aug; 213 (2): 275–285. doi: 10.2214/AJR.18.20845.

8. Tagawa ST, Vallabhajosula S, Christos PJ et al. Nanus DMPhase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer. Cancer 2019; 125 (15): 2561–2569. doi: 10.1002/cncr.32072.

9. Yadav MP, Ballal S, Tripathi M et al. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging 2017; 44 (1): 81–91. doi: 10.1007/s00259-016-3481-7.

10. Hofman MS, Violet J, Hicks RJ et al. 177Lu-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018; 19 (6): 825–833. doi: 10.1016/S1470-2045 (18) 30198-0.

11. Niaz MJ, Batra JS, Walsh RD et al. Pilot study of hyperfractionated dosing of lutetium-177-labeled antiprostate-specific membrane antigen monoclonal antibody j591 (177lu-j591) for metastatic castration-resistant prostate cancer. Oncologist 2020; 25 (6): 477–e895. doi: 10.1634/theoncologist.2020-0028.

12. Kim YJ, Kim YI. Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer: a meta-analysis. Clin Nucl Med 2018; 43 (10): 728–734. doi: 10.1097/RLU.0000000000002210.

13. Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer (VISION). [online]. Available from: https: //clinicaltrials.gov/ct2/show/NCT03511664?term=177lu&rank=9.